News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Saad Z. Usmani, MD, FACP, Levine Cancer Institute

Articles by Saad Z. Usmani, MD, FACP, Levine Cancer Institute

Third and Subsequent Line Options for Multiple Myeloma

ByAjai Chari, MD, Mount Sinai Hospital,Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center,Saad Z. Usmani, MD, FACP, Levine Cancer Institute,Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens

January 29th 2021

Updates in Relapsed/Refractory Myeloma

ByAjai Chari, MD, Mount Sinai Hospital,Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center,Saad Z. Usmani, MD, FACP, Levine Cancer Institute,Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens

January 29th 2021

Updates in Multiple Myeloma in the Frontline Setting

ByAjai Chari, MD, Mount Sinai Hospital,Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center,Saad Z. Usmani, MD, FACP, Levine Cancer Institute,Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens

January 29th 2021

Rapid Readouts: Update of CARTITUDE-1

BySaad Z. Usmani, MD, FACP, Levine Cancer Institute

June 23rd 2020

Latest Updated Articles

Updates in Multiple Myeloma in the Frontline Setting
January 29th 2021
$Updates in Relapsed/Refractory Myeloma$
Updates in Relapsed/Refractory Myeloma
January 29th 2021
Third and Subsequent Line Options for Multiple Myeloma
January 29th 2021
Rapid Readouts: Update of CARTITUDE-1
June 23rd 2020

Trending on OncLive

HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA

TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC

Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis

Dr Eads on Early Data for CDH17-Directed CAR T-Cell Therapy in R/R GI Cancers

Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg